Abstract: The present invention relates to a touch-free topical spray of halobetasol comprising a composition which is delivered through a dispensing system, wherein the composition comprises from about 0.01% w/w to about 0.5% w/w of halobetasol based on the total weight of the composition for the treatment of skin disorders, wherein the dispensing system comprises a metered valve assembly comprising a metered valve having a stem connected to an actuator, wherein the actuator is provided with an insert having an orifice diameter in a range of about 0.2 mm to about 1.5 mm, and wherein no rubbing-in is required when said composition is applied to affected skin. Said topical spray compositions offer ease of application leading to enhanced patient compliance. Further, said compositions are delivered from a dispensing system in metered doses. It also relates to processes for the preparation of the touch-free topical spray compositions.

Abstract: The present invention relates to a halobetasol topical spray system comprising: (i) a composition comprising halobetasol; (ii) a dispensing system comprising: (a) a pressurized container comprising the composition and (b) a metered valve assembly comprising a metered valve having a stem connected to an actuator, wherein the actuator is provided with an insert having an orifice diameter in a range of about 0.2 mm to about 1.5 mm, wherein the actuator is depressed for activation to expel the composition from the pressurized container forming a focused coverage area. Further, said compositions are delivered from a dispensing system in metered doses.

Abstract: The present invention relates to topical aqueous spray compositions of halobetasol. The topical aqueous spray compositions may be in the form of solutions or emulsions. It also relates to processes for the preparation of the topical aqueous spray compositions. It further relates to a method of treating topical skin conditions by administering said topical aqueous spray compositions.

Abstract: The present invention provides a stable topical pharmaceutical composition of halobetasol propionate. The present invention discloses an impurity of compound of Formula II and its process of preparation. It also relates to a method of evaluating stability of a topical pharmaceutical composition of halobetasol propionate.

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract: The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.

Abstract: The invention relates to an improved topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate; wherein silver sulfadiazine is in nanonized form.